Taros EVP Youri R. Mesmoudi was interviewed in the current Issue of CHEManager´s Section Chemistry & Life Sciences on “From Idea to Product – the principle of an extended workbench accelerates innovation in chemistry”
CHEManager Interview with Taros, Issue March 2020 Read More »
Due to current situation with the spread of the Sars-CoV-2 (“Coronavirus”) we want to share with you the latest information on how Taros Chemicals have prepared for both, the protection of our employees and partners’ health and the uninterrupted continuation of our chemistry and discovery services to our clients…
Taros Chemicals Update on COVID-19 Situation Read More »
Ahead of Oxford Global’s R&D Series Drug Discovery Virtual on 29-30 July 2020 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical R&D and the opportunities and challenges in Drug Discovery…
Oxford Global Q&A Session with Taros’ Senior Vice President Drug Discovery Read More »
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods. These drugs consist of components that stimulate the immune system and…
I3-STM research project completed Read More »
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019. In the light of Dimitrios presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that…
XPOMET Event Podcast with Taros’ CEO Read More »
The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in…
ELF continues its success story Read More »
Starting from a recently identified endogenous inhibitor of vascular calcifications, Taros Drug Discovery scientists will be working in close collaboration with the Lead Discovery Center (LDC) in Dortmund and the Institute for…
Over the next three years, Taros Chemicals will work closely with a consortium of eight partners from industry and academia (molecular biology and cellular metabolic physiology) in the search for new drugs to treat diabetes. Taros scientists will actively…
New Center of Competence for Innovative Diabetes Therapy Read More »
ZeClinics SL, a biotech firm focused on preclinical services with zebrafish, announced today that they have entered into a joint research agreement with Taros Chemicals GmbH, a company specializing in drug discovery and medicinal chemistry research, to develop novel therapies for…
CARDIOREG alliance to develop new heart regeneration therapies Read More »
Taros Chemicals, a privately owned CRO focused on serving the needs of pharmaceutical, chemical, agrochemical and biotech companies, announced today that it again obtained its CIR accreditation from French Authorities that allow eligible clients to benefit from tax credits until 2020. “We are extremely pleased that our…
Taros obtains French CIR accreditation until 2020 Read More »
Content
Contact
Taros Chemicals GmbH & Co. KG
Emil-Figge-Str. 76a
44227 Dortmund
GERMANY
© 2022 Taros Chemicals GmbH & Co. KG. All rights reserved.